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Abstract
Mortality from bacterial meningitis in African adults is significantly higher than those in better resourced settings and
adjunctive therapeutic interventions such as dexamethasone and glycerol have been shown to be ineffective. We
conducted a study analysing data from clinical trials of bacterial meningitis in Blantyre, Malawi to investigate the clinical
parameters associated with this high mortality.
Methods: We searched for all clinical trials undertaken in Blantyre investigating bacterial meningitis from 1990 to the
current time and combined the data from all included trial datasets into one database. We used logistic regression to relate
individual clinical parameters to mortality. Adults with community acquired bacterial meningitis were included if the CSF
culture isolate was consistent with meningitis or if the CSF white cell count was .100 cells/mm3 (.50% neutrophils) in HIV
negative participants and .5 cells/mm3 in HIV positive participants. Outcome was measured by mortality at discharge from
hospital (after 10 days of antibiotic therapy) and community follow up (day 40).
Results: Seven hundred and fifteen episodes of bacterial meningitis were evaluated. The mortality rate was 45% at day 10
and 54% at day 40. The most common pathogens were S.pneumoniae (84% of positive CSF isolates) and N.meningitidis (4%).
607/694 (87%) participants tested were HIV antibody positive. Treatment delays within the hospital system were marked.
The median presenting GCS was 12/15, 17% had GCS,8 and 44.9% had a seizure during the illness. Coma, seizures,
tachycardia and anaemia were all significantly associated with mortality on multivariate analysis. HIV status and
pneumococcal culture positivity in the CSF were not associated with mortality. Adults with community acquired bacterial
meningitis in Malawi present with a severe clinical phenotype. Predictors of high mortality are different to those seen in
Western settings. Optimising in-hospital care and minimising treatment delays presents an opportunity to improve
outcomes considerably.
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Introduction
Since the beginning of the HIV epidemic, many high
prevalence Sub-Saharan African countries have reported an
increase in patients presenting to health care facilities with acute
bacterial meningitis (ABM) [1,2]. Following the introduction of
penicillin in the 1950s mortality rates from ABM in resource rich
settings have improved from 45–50% to 11–25% in the last
decade [3–7]. This improvement is associated with early
institution of antibiotic therapy and better supportive care [4,8].
In contrast, adult ABM mortality rates in sub-Saharan Africa have
been reported to vary between 54–70% without any change over
time [9–12] and survivors experience significantly higher rates of
disabling neurological sequelae compared to European patients
[13].
Interventions such as adjunctive dexamethasone and glycerol
have failed to impact on this high mortality in large randomised
controlled trials in Malawi and thus ABM remains a considerable
clinical challenge [14,15]. In European and American cohorts
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important risk factors for poor outcome including advanced age,
acute hyperglycaemia and immunosuppression have been identi-
fied [16,17], however data are lacking from resource-poor settings.
We took advantage of the large body of prospective clinical trial
and observational data collected in Blantyre, Malawi to investigate
these dramatically high adult ABM mortality rates and identify
risk factors for a poor prognosis.
Methods
Setting
Queen Elizabeth Central Hospital (QECH), Blantyre is a 1250-
bed government funded hospital with free care at the point of
delivery that admits 50,000 patients per year. QECH serves a
population of approximately 1 million including the city of
Blantyre. The diagnostic laboratory at the Malawi Liverpool
Wellcome Trust Clinical Research Programme (http://www.mlw.
medcol.mw) has provided a quality controlled cerebral spinal fluid
(CSF) and blood culture service for QECH for more than 10 years.
Study Selection
We identified all clinical trials and observational studies
(published and unpublished) undertaken at the Department of
Medicine, College of Medicine, QECH between 1990-to the
current time, where adults with ABM were recruited prospectively
and data were freely available. Database access for each study was
obtained from the principal investigator.
Inclusion and Exclusion Criteria
Included participants were over 13 years of age (adult ward
admission age) and enrolled in a clinical study of ABM at QECH
with either CSF proven microbiological evidence of ABM, or a
high clinical index of suspicion of ABM plus a CSF white cell
count that was .50% neutrophils and .100 cells/mm3 in HIV
negative or 5 cells/mm3 in HIV positive. The latter was selected
because the CSF inflammatory response in ABM may be
attenuated in HIV infected African adults [18]. Participants were
excluded if the CSF microscopy or culture was positive for
Cryptococcus neoformans or Mycobacterium tuberculosis, if the CSF white
cells were .50% lymphocytes, or on study specific criteria, such as
type two diabetes for the glycerol trial [11].
Outcome Analysis
The outcome measure for included subjects was mortality which
was measured at day 10 and at day 40. Day 40 was prospectively
agreed as the last follow up time point in included studies. Day 0
was recorded as the date and time of entry into the hospital; day 1
was 24 hours from this point.
Variables were standardised and a single database was created.
The first recorded clinical observations on admission were used.
Eighteen clinical and demographic parameters were selected on
the basis of previous published associations and suspected risk
factors, and subjected to analysis for associations with death
[16,17,19]. Age .40 was selected as the current life expectancy in
Malawi is 45–50 years. Glycerol receipt was included to account
for the excess mortality seen in that trial [13]. The analysis plan
was designed first to test all 18 variables against mortality using
univariate analysis and enter these variables into a multivariate
model to test the strength of any associations seen. Clinically
relevant groupings for continuous variables were created for the
multivariate model to aid interpretation of the results. We have
reported the seasonal nature of invasive pneumococcal disease in
Malawi, and used this data to investigate if mortality was also
seasonal [9,20].
Ethical Approval
All constituent studies had been approved by the College of
Medicine Research and Ethics Committee in Malawi, and by the
Liverpool School of Tropical Medicine Research Ethics Commit-
tee and conformed to institutional guidelines. All participants in
the included clinical trials and studies gave written informed
consent, or this was given by a named guardian if the participant
was under 18 years of age.
Statistical Methods
Data were analysed using SPSS/PASW version 20. Univariate
analysis was performed for each variable. For continuous
variables, parametric (Student t) and non-parametric (Mann-
Whitney U) tests were used to compare survivors and non-
survivors; Fisher exact/chi-square tests were used to compare
categorical variables. A multivariate analysis model was generated
using backwards stepwise logistic regression methods to estimate
the influence of each variable on clinical outcome. Each model
was compared at each step with the previous model and only
variables with on-going significance remained in the analysis. Data
from the final model retaining all significant variables were
reported. The strength of relationships was expressed using odds
ratios with 95% confidence intervals. All statistical tests were two-
tailed, and a p value of ,0.05 was used to denote statistical
significance. Due to the heterogeneous nature of the studies
included, some significant variables had missing data; if .50% of
the data were missing, these variables were excluded from the
multivariate analysis. The multivariate analyses were repeated
using multiple imputation methods to enable subjects with missing
data to be included; this did not alter the results and these analyses
are not presented.
Results
Study and Patient Selection
Five studies were identified. One observational study was
excluded as it was conducted prior to the introduction of
ceftriaxone in 2001 under different admission conditions [9].
One vaccine trial was excluded as specific clinical data for the
patients with meningitis were not available [21]. The three
included studies were two clinical trials, testing dexamethasone
[11] or glycerol [15] adjunct therapy and an unpublished
prospective cohort study investigating risk factors for mortality
(Table 1). All studies recruited patients over 13–16 years with
ABM and used ceftriaxone as the first line antibiotic. A total of 891
participants were identified. We excluded 115 patients who had
either proven fungal (n = 52) or tuberculous meningitis (TBM)
(n= 25), or a CSF white cell count of ,5 cells/mm3 (n= 38). A
further sixty one patients were excluded because no mortality data
were available at day 10 yielding 715 cases for the analyses. We
excluded a relatively high proportion of participants from the
cohort study (118/161) compared to 26 from the glycerol trial and
32 from the dexamethasone trial. This was due to a high number
of patients in this database either not meeting the white cell count
inclusion criteria for this analysis or having mortality data
available. Free access to HIV treatment become routinely
available during the study period; co-trimoxazole prophylaxis in
2002 and anti-retroviral therapy (ART) from 2004 [20].
Clinical and Laboratory Findings
The median age was 31 years (inter-quartile range IQR 25–38)
and half were female (50.3%). 20 participants (2.8%) were
adolescents. 608/695 (87%) of those tested were HIV antibody
positive, of which 36 (5.9%) were on ART (Table 2). CD4 cell
Mortality from Bacterial Meningitis in Malawi
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Table 1. Details of included studies.
Study name Study dates Type of study Intervention tested








2001–2004 Randomised Controlled Trial Intravenous Dexamethasone
adjunct to antibiotics
465 (433) 233 (54)
Glycerol in Adult
Meningitis (GLAM) [15]
2006–2008 Randomised Controlled Trial Oral glycerol adjunct to
antibiotics
265 (239) 129 (54)
Cohort observational
study (unpublished)
2009 Observational cohort No intervention 161 (43) 22 (51.1*)
*this study only collected data to day 10 hospital discharge and not day 40 follow up.
doi:10.1371/journal.pone.0069783.t001
Table 2. Demographics/characteristics of study patients.
Characteristic on presentation Number of observations available Value (% or Inter Quartile Range IQR)
Clinical observations
Deaths at day 10 715 324 (45.3)
Total deaths at 40 day follow up 668 363 (54.3)
Female sex 715 364 (50.3)
HIV positive 694 607 (87)
Antiretroviral therapy 607 35 (5.7)
Out of hours admission 655 315 (48)
Median age 715 31 (25–38)
Headache or history of acute headache 691 683(99)
Neck stiffness 715 536 (75)
Photophobia 683 106 (15.5)
Median Glasgow Coma Score recorded 649 12.0 (9–14)
GCS.8–,11 (significant alteration of mental status) 649 169(26)
GCS,8 (coma) 649 113 (17.4)
Recorded acute seizure 714 319 (44.9)
Seizure post discharge 416 89 (21)
Median mean arterial blood pressure (mmHg)
recorded
593 86 (79.9–96.7)
Median pulse (bpm) 596 100 (88–116)
Mean temperature (uC) recorded 668 38.1 (37.2–39)
Median recorded oxygen saturations 207 96% (93–97)
Microbiology
Positive CSF culture 712 419 (58.8); S.pneumoniae n= 356 (84.9); N.meningitidis
n= 17 (4.1); H.influenzae n= 3 (0.7); Other n = 43 (10.2)
Median CSF white cell count (cells/mm3) 707 480 (170–1680)
Positive blood culture 660 185 (27.8%); S.pneumoniae n= 126 (68.4); N.meningitidis
n= 8 (4.1); H.influenzae n= 1 (0.4); Enteric Gram
negative n = 27 (14.9); Other n = 23 (12.4)
Blood tests Median (IQR)
Sodium (mmol/L) 43 135 (130.9–139.1)
Haemoglobin (g/dL) 643 10.8 (9.0–12.7)
Glucose (mmol/L) 546 6.7 (6.0–98.7)
Creatinine (mg/dL) 40 1.1 (0.9–1.2)
doi:10.1371/journal.pone.0069783.t002
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counts were not routinely measured during the time period
studied.
The overall mortality rate was 45.3% in hospital by day 10, and
54.3% by day 40, with no significant difference across the three
studies (Table 2). Altered mental status and coma were common.
The median presenting Glasgow Coma Score (GCS) was 12 (IQR
9–14.0) and 113 (17.4%) of participants presented with a GCS of 8
or less. 319 (44.6%) participants experienced an acute seizure and
89 participants experienced seizures after discharge. Fever .38uC
(88.5%), headache or history of headache (99%) and neck stiffness
(75%) were common, however photophobia was rare (15.5%).
Septic shock was uncommon; the median pulse rate was 100 beats
per minute (IQR 88–116) and the median mean arterial pressure
(MAP) was 86 mmHg (IQR 79.9–96.7). Neurological disability
(with the exception of post discharge seizures) and hearing loss
were reported differently across the included studies and could not
be sufficiently standardised for inclusion on the analysis.
CSF culture was positive in 419 of 712 specimens (59%).
Streptococcus pneumoniae was the most common isolate (356/419,
85%) followed by Neisseria meningitidis (17/419, 4%) (Table 2).
Other isolates included Non-typhoidal Salmonellae (NTS), Esch-
erichia coli, Group A streptococci and Haemophilus influenzae. The
median CSF white cell count was 480 cells/mm3 (IQR 170–1680).
CSF opening pressure was not routinely recorded. Blood cultures
were positive in 185/664 (28%) of individuals; the most commonly
isolated organisms being S.pneumoniae (126/185, 68%), enteric
gram negative organisms (27/185, 15%) and N.meningitidis (8/185,
4%). Of 352 pneumococcal CSF isolates where paired blood
culture data were available, 139 (40%) were positive. Compre-
hensive data on antimicrobial resistance were not available.
Pneumococcal serotype was determined in 128 of 352 isolates; 56
(43.8%) were serotype 1. Other serogroups were 6 (4.7%), 7
(3.1%), 9 (4.7%), 12 (3.9%), 14 (4.7%), and 19 (3.1%). Mortality
was 59% (33/56) for the participants infected with serotype 1 and
50.1% (36/71) for the other serogroups. Available data were too
few to analyse this trend further.
Delays to Presentation to Hospital and Clinical Care
Presentation out of routine working hours comprised 318
(44.5%) of admissions. For a subset of patients with culture proven
ABM ‘the observational cohort’, (n = 26) data were collected
prospectively relating to the patient pathway on a standard form to
investigate delays in presentation, investigation and initiation of
therapy. Nine of 26 patients (35%) died before day 10. Median
self-reported journey time to QECH was 0.8 hours (IQR 0.5–1.6)
in non-survivors, and 1.5 hours (IQR 0.7–2.0) in survivors.
Median time from presentation to medical review was 2.8 hours
(IQR 0.8–5.8) in non-survivors and 1 hour (IQR 0.6–3.0) in
survivors. The median time from presentation at the hospital with
meningitis to receipt of intravenous antibiotics was 5.0 hours (IQR
2.5–8.9) in non-survivors and 2.7 hours (IQR 1.7–6.0) in survivors.
No time difference reached statistical significance.
Prognostic Clinical Features
Eighteen parameters were subjected to univariate analysis for
associations with survival at day 10 (n = 715) and day 40 (n= 668).
There was no statistically significant difference between these two
time points for any of the variables except pneumococcal culture
and therefore the day 40 follow up data are presented (Table 3).
The following clinical parameters were significantly associated
with poor outcome on univariate analysis: age, clinical presenta-
tion with altered mental status, acute and post discharge seizures,
hypoxaemia, tachycardia, hyponatraemia, anaemia and treatment
with glycerol. Neither gender, out of hours admission, HIV
antibody status, blood glucose, mean arterial blood pressure,
anuria, respiratory rate, nor serum creatinine were associated with
poor outcome (Table 3). Of the 339 participants with S.pneumoniae
isolated from the CSF, 181 (54%) died and 158 (46%) were alive at
day 40 OR 0.923 (0.68: 1.25) p = 0.61. As culture of S.pneumoniae
in the CSF and HIV status have been associated with mortality in
other studies of bacterial meningitis [22,23] these data were added
to the multivariate model with the other tested variables. Coma
scores were grouped into three categories: ,8, 8–11 and .11.
Oxygen saturations, post discharge seizures, respiratory rate,
anuria, creatinine and sodium had .50% of data missing and
were excluded. Seizures were divided into acute (pre-hospital and
in hospital) and seizures during follow up. Haemoglobin and pulse
rate were divided into clinically significant groupings.
Presentation with coma was the strongest independent predictor
of outcome after multivariate analysis; OR for death with a
GCS,8/15 was 5.9 (95% CI 3.31: 10.86) p,0.001, GCS of 8–11
was 1.665 (1.08: 2.5 ) p = 0.007. Acute seizures were associated
with death, OR 1.55 (1.08: 2.24) p = 0.019. The severity of
anaemia was associated with a corresponding increasing risk of
mortality, OR death of haemoglobin (Hb) 5–8 g/dL was 3.41
(1.61: 7.23) p = 0.001; at Hb,5 g/dL the OR was 6.34 (1.86:
21.62) p= 0.003. Every 1 g/dL increase in haemoglobin was
associated with a 12% reduction in mortality, OR 0?88 (0.82–
0.94). Tachycardia .120 bpm was also associated with death, OR
1.80 (1.08: 2.99) p = 0.023. Glycerol receipt was independently
associated with mortality 1.88 (1.09: 3.25) p = 0.023. Age .40
years was not significant, OR 1.33 (0.86: 2.06) p= 0.20.
Neither CSF pneumococcal culture positivity nor HIV status
were significantly associated with mortality at day 40. The OR of
death were 0.70 (0.49: 1.02) p = 0.06 for pneumococcal infection,
and 1.18 (0.70: 2.00) p= 0.52 for HIV infection. No parameter
reaching non-significance at the univariate level was shown to
have significant association at the multivariate level.
Mortality was not seasonal; 279 (36%) of cases presented in the
cold winter season (May-September), with 145 (52%) deaths and
388 (64%) cases presented during the remaining hot months of the
year with 217 (56%) deaths p = 0.34 (Figure 1).
Discussion
Adults and adolescents presenting to hospital in Malawi with
bacterial meningitis are young, largely HIV positive and have a
very high mortality rate, contrasting significantly with published
data from high income countries [3,24]. Eighty seven percent of
participants in our study were HIV antibody positive compared to
the QECH medical inpatient rate of 76% and a current adult
national population prevalence of 12% [25]. These figures are
similar to data from meningitis patients in other African centres
[12,18,26]; invasive infection with Streptococcus pneumoniae is more
common in HIV infected than HIV uninfected individuals in sub-
Saharan Africa [21,27]. HIV infected adults in our setting have
higher rates of pneumococcal carriage than HIV uninfected
individuals [Kamng’ona et al 2013 unpublished]. The high rates
of bacterial meningitis in HIV positive adults may be potentially
related to increased susceptibility to S.pneumoniae infection via
altered mucosal and cell-mediated immunity [28]. Immunocom-
promise has been associated with ABM in adults, but HIV has not
to date been proven to be an independent risk factor [9,23,24,29].
In contrast to the apparently increased frequency of disease, HIV
sero-positivity was not significantly associated with mortality.
However the numbers of HIV negative patients were small, with
an additional very small number where no sero-status was known.
All the HIV antibody positive participants in this study were
Mortality from Bacterial Meningitis in Malawi
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Table 3. Predictors of mortality at day 40 on univariate and multivariate analysis.
Parameter Day 40 Univariate (unadjusted) Multivariate (adjusted)**
Alive Dead Odds ratio (95% CI) p Odds ratio (95% CI) p
Sample size 304 363
Age mean (sd) 31.5 (10.7) 34.2 (11.4) 1.023 (1.009: 1.038)` 0.002
#40 years 256 285 (52.7%) – – – –
.40 years 48 78 (61.9%) 1.460 (0.981: 2.171) 0.062 1.327 (0.858: 2.055) 0.204
Gender male 149 177 (54.3%) – – – –
female 155 186 (54.5%) 1.010 (0.754: 1.370) 0.948 0.894 (0.621: 1.287) 0.548
HIV status negative 43 37 (46.2%) – – – –
positive 254 316 (55.4%) 1.446 (0.904: 1.370) 0.124 1.184 (0.700: 2.001) 0.528
not known 7 10
Out of hours admission no 138 173 (55.6%) – – – –
yes 134 162 (54.7%) 0.964 (0.700: 1.328) 0.824 0.949 (0.661: 1.362) 0.777
not known 32 28
GCS mean (sd) 12.2 (2.8) 10.2 (3.6) 0.825 (0.786: 0.867)` ,0.001
$11 205 168 (45.0%) – – – –
8–11 69 94 (57.7%) 1.662 (1.146: 2.411) 0.007 1.665 (1.086: 2.554) 0.007
,8 20 84 (80.8%) 5.125 (3.021: 8.695) ,0.001 5.999 (3.314: 10.861) ,0.001
not known 10 17
1 or more acute no 216 207 (48.9%) – – – –
seizure episodes yes 87 156 (64.2%) 1.871 (1.353: 2.588) ,0.001 1.552 (1.075: 2.241) 0.019
not known 1 0
Seizure post-discharge no 271 57 (17.4%) – –
yes 23 64 (73.6%) 13.230 (7.591: 23.057) ,0.001 { {
not known 10 242
SpO2 mean (sd) 95.2 (2.7) 93.5 (5.7) 0.888 (0.806: 0.978)
` 0.016 { {
.95 52 48 (48.0%) – –
92–95 26 32 (55.2%) 1.333 (0.696: 2.552) 0.385 { {
,92 11 29 (72.5%) 2.856 (1.287: 6.339) 0.010
not known 215 254
Pulse rate mean (sd) 96.9 (18.6) 103.1 (19.0) 1.018 (1.008: 1.027)` ,0.001
,100 172 162 (48.5%) – – – –
100–120 39 57 (59.4%) 1.552 (0.979: 2.459) 0.061 1.422 (0.844: 2.397) 0.186
.120 44 76 (63.3%) 1.834 (1.194: 2.816) 0.006 1.800 (1.084: 2.987) 0.023
not known 49 68
MAP (mmHg) mean (sd) 89.7 (13.0) 89.0 (15.5) 0.996 (0.985: 1.008)` 0.530
,90 152 174 (53.4%) – – – –
90–100 57 66 (53.7%) 1.011 (0.667: 1.533) 0.957 0.972 (0.622: 1.520) 0.902
.100 44 56 (56.0%) 1.112 (0.708: 1.745) 0.645 1.107 (0.636: 1.925) 0.720
not known 51 67
Respiratory rate mean (sd) 23.8 (9.6) 24.2 (6.3) 1.007 (0.954: 1.064)` 0.790 { {
not known 246 299
Anuria no 208 252 (54.8%) – – – –
not known 96 111
CSF culture positive for
S.pneumoniae
no 145 180 (55.4%) – – – –
yes 158 181 (53.4%) 0.923 (0.680: 1.253) 0.606 0.704 (0.488: 1.016) 0.061
not known 1 2
Plasma glucose mean (sd) 7.3 (2.7) 7.4 (3.8) 1.007 (0.957: 1.059)` 0.793
(mmol/L) $9 46 45 (49.5%) – – – –
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WHO clinical stage 3 or 4, classified as such by the diagnosis of
bacterial meningitis as stage 3, becoming stage 4 with one prior
documented invasive bacterial infection. In children in sub-
Saharan Africa HIV may be a risk factor for death from ABM,
[22,26,30] but data in African adults from other centres are
lacking. Although epidemiological data are scarce, preliminary
culture positive ABM incidence estimates for 2010 are 12.6 cases
of ABM per 100 000 adult population in Malawi [Wall, Everett,
et al 2013 unpublished] compared to 1.38–3.2/100 000 adults in
high income countries [16,23,24].
A striking finding from this very large ABM dataset was the
excessive mortality which is much higher than in series from
industrialised countries and has remained unchanged for 10 years
[9,16,23,24]. This is in direct contrast with a large study of ABM
in Holland (n= 696), where patients presented early and the
overall mortality was 21%. In that cohort over 50% of patients
presented within 24 hours of symptom onset. 14% of participants
Figure 1. Cases and mortality by month of admission at day 40 follow up.
doi:10.1371/journal.pone.0069783.g001
Table 3. Cont.
Parameter Day 40 Univariate (unadjusted) Multivariate (adjusted)**
Alive Dead Odds ratio (95% CI) p Odds ratio (95% CI) p
6–9 90 102 (53.1%) 1.159 (0.703: 1.909) 0.563 1.292 (0.748: 2.234) 0.358
#6 101 123 (54.9%) 1.245 (0.764: 2.028) 0.379 1.423 (0.763: 2.653) 0.268
not known 67 93
Haemoglobin (g/dL) mean (sd) 11.4 (2.9) 10.5 (2.9) 0.893 (0.841: 0.949)` ,0.001
.14 50 32 (39.0%) – – – –
11–14 95 101 (51.5%) 1.661 (0.983: 2.807) 0.058 1.836 (1.006: 3.352) 0.048
8–11 104 134 (56.3%) 2.013 (1.206: 3.360) 0.007 2.598 (1.422: 4.747) 0.002
5–8 26 45 (63.4%) 2.704 (1.404: 5.210) 0.003 3.404 (1.603: 7.229) 0.001
,5 4 11 (73.3%) 4.297 (1.259: 14.662) 0.020 6.343 (1.861: 21.624) 0.003
not known 67 93
Glycerol treatment no 58 53 (47.7%) – – – –
yes 47 76 (61.8%) 1.770 (1.051: 2.978) 0.032 1.884 (1.092: 3.249) 0.023
not known 199 93
Na (mmol/L)* median
(range)
137 (125:199) 132 (115:152) 0.928 (0.834: 1.032)` 0.166 { {
not known 283 341
Creatinine (mg/dL)* median
lpar;range)
1.05 (0.7:1.5) 1.15 (0.5:10.8) 4.441 (0.682: 28.925)` 0.119 { {
not known 286 341
{proportion of missing data .50% so variable excluded from multivariate analysis.
`odds ratio for a unit increase in predictor variable.
*values at day 10 presented as too few observations available at day 40 data for a meaningful analysis.
**4 cases excluded due to missing observations.
doi:10.1371/journal.pone.0069783.t003
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in Holland vs. 17% in Malawi presented in coma (GCS,8/15),
5% vs. 44.9% had a seizure during the illness and 20% vs. 22%
presented with a tachycardia .120 bpm [16]. The studies
included in this analysis all had broad inclusion criteria and
recruited patients admitted with ABM at night and weekends, and
the included cases were representative of all adults with ABM
presenting to our centre, the risk of selection bias was low. Some
cases in the studies were missed due to early mortality, this was
predominately seen in the glycerol study, but as clinical data were
not available for these participants, we were not able to include
these cases in the analysis. Furthermore the glycerol study was
stopped early by the study safety monitors due to higher than
expected mortality in the glycerol group. The analysis was re-run
without data from participants who received glycerol, no
significant differences were found. Data from these participants
were included in the database as the presenting characteristics
were equally matched with the other studies and glycerol is shown
to be an independent predictor of mortality.
Early access to resuscitation and antibiotic treatment has been
instrumental in reducing mortality rates from paediatric meningitis
[4,31–34]. Our limited analysis of the patient journey suggests
delays in clinical management may be important. The median five
hour delay before non-survivors received antibiotics may have
contributed to poor survival as shown in other series, although our
data are small [4,8]. These delays were predominately due to staff
resource constraints and the use of a complex triage system. Delay
to prompt medical review, acute resuscitation and suboptimal
intensive care support may also have contributed. Preliminary
data from our centre suggests that pre-hospital delays in seeking
treatment for meningitis stem from a lack of understanding and
recognition of the serious nature of the illness, cultural inhibitions
and long, expensive journeys to hospital [Desmond 2013 PLOS
ONE in press]. The self-reported journey times recorded must be
interpreted with caution as few patients owned a watch or mobile
phone.
Similarly to the Dutch cohort, we show that coma and
tachycardia are independently associated with death on multivar-
iate analysis [16]. In addition we show acute seizures, glycerol
administration and anaemia are independent predictors of
mortality in Africa. Anaemia is extremely common in this setting
and may generally be associated with a poor clinical outcome in
hospital [11,35,36], however its independent association with poor
outcome from meningitis warrants further investigation.
S.pneumoniae was the most common organism isolated from CSF.
Only 4% of cases were due to N. meningitidis, all of whom survived.
Malawi is south of the African meningitis belt, and meningococcal
epidemics occurring during the study period did not affect Malawi.
Our results therefore are not generalizable to that region, but are
applicable to other African countries in sub-Saharan Africa with
high rates of HIV infection and invasive pneumococcal disease.
Mortality was highest in those with S.pneumoniae serotype 1 [14].
Serotype 1, is included in the 13 valent pneumococcal conjugate
vaccine introduced in Malawi in 2011, and surveillance of the
impact of vaccination on invasive pneumococcal disease is likely to
be important [37].
In contrast to Western data, a sub-analysis (not presented) did
not show an association between S.pneumoniae culture positivity and
poor neurological outcome or seizures in survivors [16].
All studies used ceftriaxone as the first line antibiotic. Only a
very small proportion were taking antiretroviral therapy (ART)
and we do not have data on co-trimoxazole use. We reported
pneumococcal resistance between 2000–2009 to the following
antibiotics: multi-drug resistance (co-trimoxazole, tetracycline and
chloramphenicol) in 30%, penicillin in 15%, ceftriaxone in 0%;
co-trimoxazole resistance increased from 74% to 93% [20] [38].
Our study recorded a significant number of participants who had a
negative CSF culture. All data were from clinical studies with strict
inclusion criteria including expert clinical evaluation. S.pneumoniae
is a fastidious organism and culture has a low sensitivity, PCR and
antigen detection tests were not available. Although our CSF
WCC inclusion criteria was .5 cells/mm3 in HIV positive
participants, the median WCC was significantly higher than this
(480 cells/mm3 IQR 170–1680). It is unlikely that any participants
had a CSF inflammatory response due to seizures alone [39]. All
CSF specimens were routinely cultured for Cryptococcus neofor-
mans but not M.tuberculosis. Specific TB meningitis (TBM) data
from our centre demonstrated a median CSF WCC of only 40
cells/mm3 (IQR 0–240) in TBM, 10 fold lower than our study of
ABM [40]. All participants with clinically suspected TBM were
excluded from the included studies and started on TB treatment. It
is unlikely that a significant number of remaining participants in
this database had un-diagnosed TBM but cases of TBM cannot
completely be excluded.
Some findings contrasted with other studies. Hyponatraemia
was associated with mortality, although the numbers were small,
contrasting with Dutch data, where no association was seen [19].
Hyperglycaemia was uncommon in our study, although partici-
pants with diabetes were excluded from one of the studies [13].
Abnormal glucose levels were not associated with poor outcome,
although other studies have shown an association [17]. We were
unable to take these observations forward for multivariate analysis
due to small numbers of data available. All the studies were
undertaken in a profoundly resource-constrained environment
where very limited access to laboratory monitoring and intensive
care support was available. Further work from our centre will
explore these potential associations in the future.
Data heterogeneity limited our analysis. All data were collected
prospectively but the lack of uniform data acquisition across the
studies and missing data limited our ability to analyse each trend
fully. We used random imputation models to test the robustness of
our findings, but where the proportion of missing data was higher
than collected data those variables could not be included. We were
not able to evaluate some of the other indicators that are
prognostically significant in other settings. We were unable to
stratify our results by CD4 count. A small proportion of adults
screened by the included clinical trials died before recruitment,
refused consent or were excluded due to study specific criteria, but
overall the majority of adults with bacterial meningitis presenting
to our centre were enrolled in these studies and the risk of selection
bias is low. The consistency of the numbers recruited over each
time period and mortality suggests that the confounding effect of
time on the analysis is minimal. Despite the introduction of major
public health interventions in Malawi over the time period studied
the mortality rate from bacterial meningitis remains unchanged.
This study is the largest clinical analysis of bacterial meningitis
in adults and adolescents in Africa to date, and the first to
investigate the role of clinical presentation and key physiological
parameters in outcome. Our findings are likely to be generalisable
to much of sub Saharan Africa. Coma, seizures, tachycardia and
anaemia all independently predict a poor outcome. Disease
severity at presentation is likely to be worsened by delays in
presentation to hospital and further in-hospital delays. Early
antibiotics and goal directed resuscitation have been shown to
reduce mortality significantly in sepsis [41], but have not been
tested to date in bacterial meningitis. Further research in Africa is
needed urgently to test this approach in resource limited settings in
an attempt to improve the in-hospital management of bacterial
meningitis and the very high mortality rates.
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